2022 - Research.com Best Scientist Award
David M. Holtzman focuses on Alzheimer's disease, Internal medicine, Endocrinology, Apolipoprotein E and Neuroscience. His studies deal with areas such as Dementia, Cerebrospinal fluid and Immunology as well as Alzheimer's disease. The study incorporates disciplines such as Clusterin and Oncology in addition to Internal medicine.
His Endocrinology research incorporates themes from In vivo, Genetically modified mouse and Amyloid precursor protein. His studies in Apolipoprotein E integrate themes in fields like Receptor, LRP1, Transgene and Lipoprotein. His Neuroscience research is multidisciplinary, incorporating perspectives in Neurotrophin and Programmed cell death.
His main research concerns Alzheimer's disease, Internal medicine, Disease, Pathology and Endocrinology. David M. Holtzman usually deals with Alzheimer's disease and limits it to topics linked to Amyloid and P3 peptide. His work on Internal medicine is being expanded to include thematically relevant topics such as Oncology.
His Disease study which covers Neuroscience that intersects with Neurodegeneration. His research on Pathology frequently links to adjacent areas such as In vivo. In his research, Microglia is intimately related to Cell biology, which falls under the overarching field of Apolipoprotein E.
David M. Holtzman mainly investigates Apolipoprotein E, Disease, Internal medicine, Alzheimer's disease and Dementia. His Apolipoprotein E research incorporates elements of Neurodegeneration, TREM2, Microglia, Cell biology and Amyloid. His research investigates the connection between Disease and topics such as Neuroscience that intersect with problems in Senile plaques and Neuropathology.
His biological study spans a wide range of topics, including Endocrinology and Oncology. David M. Holtzman has researched Alzheimer's disease in several fields, including Amyloid β, Bioinformatics, Pathogenesis, Gastroenterology and Amyloidosis. His research integrates issues of Microbiome and Down syndrome in his study of Dementia.
His primary scientific interests are in Alzheimer's disease, Dementia, Apolipoprotein E, Amyloid and Internal medicine. Alzheimer's disease is a subfield of Disease that David M. Holtzman investigates. His study looks at the intersection of Dementia and topics like Neurodegeneration with Tau protein.
His work deals with themes such as Transgene, TREM2, Microglia, Allele and Innate immune system, which intersect with Apolipoprotein E. The concepts of his Amyloid study are interwoven with issues in Receptor and Positron emission tomography, Neuroscience, Isolated brain. The various areas that David M. Holtzman examines in his Internal medicine study include White matter, Endocrinology and Calpain.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
The Diagnosis of Mild Cognitive Impairment due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease
Marilyn S. Albert;Steven T. DeKosky;Dennis Dickson;Bruno Dubois.
Clinical and Biomarker Changes in Dominantly Inherited Alzheimer’s Disease
Randall J. Bateman;Chengjie Xiong;Tammie L.S. Benzinger;Anne M. Fagan.
The New England Journal of Medicine (2012)
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease
Clifford R. Jack;David A. Bennett;Kaj Blennow;Maria C. Carrillo.
Alzheimers & Dementia (2018)
National Institute of Neurological Disorders and Stroke–Canadian Stroke Network Vascular Cognitive Impairment Harmonization Standards
Vladimir Hachinski;Costantino Iadecola;Ron C. Petersen;Monique M. Breteler.
Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease
Ronald B. DeMattos;Kelly R. Bales;David J. Cummins;Jean-Cosme Dodart.
Proceedings of the National Academy of Sciences of the United States of America (2001)
The Role of Apolipoprotein E in Alzheimer's Disease
Jungsu Kim;Jacob M. Basak;David M. Holtzman.
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrier.
Masayoshi Shibata;Shinya Yamada;S. Ram Kumar;Miguel Calero.
Journal of Clinical Investigation (2000)
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Abeta42 in humans.
Anne M Fagan;Mark A Mintun;Robert H Mach;Sang-Yoon Lee.
Annals of Neurology (2006)
Alzheimer’s Disease: The Challenge of the Second Century
David M. Holtzman;John C. Morris;Alison M. Goate.
Science Translational Medicine (2011)
Immunization reverses memory deficits without reducing brain Aβ burden in Alzheimer's disease model
Jean Cosme Dodart;Kelly R. Bales;Kimberley S. Gannon;Stephen J. Greene.
Nature Neuroscience (2002)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: